Suppr超能文献

终末期肝病患者的姑息治疗

Palliative Care for Patients with End-Stage Liver Disease.

作者信息

Philips Cyriac A, Kedarisetty Chandan K

机构信息

Department of Clinical and Translational Hepatology and the Monarch Liver Laboratory, Rajagiri Hospital, Aluva, Kerala, India.

Department of Hepatology and Liver Transplantation, Gleneagles Global Hospital, Hyderabad, India.

出版信息

J Clin Exp Hepatol. 2023 Mar-Apr;13(2):319-328. doi: 10.1016/j.jceh.2022.08.003. Epub 2022 Aug 13.

Abstract

End-stage liver disease (ESLD) is the culmination of progression of chronic liver disease to cirrhosis, decompensation, and chronic liver failure, featuring portal hypertension or hepatocellular failure-related complications. Liver transplantation offers improved long-term survival for these patients but is negatively influenced by donor availability, financial constraints in developing countries, active substance abuse, progression of disease or malignancy on wait-list, sepsis and extrahepatic organ involvement. In this context, palliative care (PC), an interdisciplinary medical practice that aim to prevent and relieve suffering, offers best possible quality of life and is not limited to end-of-life care. It also encompasses achievable goals such as symptom control and aggressive disease-modifying treatments or interventions that beneficially alter the natural course of the disease to offer curative intend. In this narrative review, we discuss the prognostic factors that define disease course in ESLD, various indications and challenges in PC for advanced cirrhosis and management options for major symptom burden in patients with ESLD based on evidence-based best practice.

摘要

终末期肝病(ESLD)是慢性肝病进展至肝硬化、失代偿和慢性肝衰竭的最终阶段,其特征为门静脉高压或与肝细胞功能衰竭相关的并发症。肝移植可提高这些患者的长期生存率,但受到供体可用性、发展中国家的经济限制、药物滥用、等待名单上疾病进展或恶性肿瘤、败血症和肝外器官受累等因素的负面影响。在此背景下,姑息治疗(PC)作为一种旨在预防和减轻痛苦的跨学科医疗实践,可提供尽可能好的生活质量,且不限于临终关怀。它还包括可实现的目标,如症状控制、积极的疾病改善治疗或干预措施,这些措施可有益地改变疾病的自然进程,以实现治愈目的。在这篇叙述性综述中,我们根据循证最佳实践,讨论了定义ESLD疾病进程的预后因素、晚期肝硬化PC的各种适应症和挑战,以及ESLD患者主要症状负担的管理选择。

相似文献

1
Palliative Care for Patients with End-Stage Liver Disease.终末期肝病患者的姑息治疗
J Clin Exp Hepatol. 2023 Mar-Apr;13(2):319-328. doi: 10.1016/j.jceh.2022.08.003. Epub 2022 Aug 13.
2
Diagnosis and Management of Cirrhotic Cardiomyopathy.肝硬化性心肌病的诊断与管理
J Clin Exp Hepatol. 2022 Jan-Feb;12(1):186-199. doi: 10.1016/j.jceh.2021.08.016. Epub 2021 Aug 21.
5
Model for End-stage Liver Disease.终末期肝病模型
J Clin Exp Hepatol. 2013 Mar;3(1):50-60. doi: 10.1016/j.jceh.2012.11.002. Epub 2012 Dec 1.
10
Recompensation in Cirrhosis: Current Evidence and Future Directions.肝硬化的代偿:当前证据与未来方向
J Clin Exp Hepatol. 2023 Mar-Apr;13(2):329-334. doi: 10.1016/j.jceh.2022.08.002. Epub 2022 Aug 18.

本文引用的文献

1
Gut Microbiome and Alcohol-associated Liver Disease.肠道微生物群与酒精性肝病
J Clin Exp Hepatol. 2022 Sep-Oct;12(5):1349-1359. doi: 10.1016/j.jceh.2021.12.016. Epub 2022 Jan 4.
4
Baveno VII - Renewing consensus in portal hypertension.《巴韦诺 VII 共识:门静脉高压领域的新共识》
J Hepatol. 2022 Apr;76(4):959-974. doi: 10.1016/j.jhep.2021.12.022. Epub 2021 Dec 30.
9
Evidence-based clinical practice guidelines for liver cirrhosis 2020.《2020年肝硬化循证临床实践指南》
Hepatol Res. 2021 Jul;51(7):725-749. doi: 10.1111/hepr.13678. Epub 2021 Jul 6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验